Innovative solutions for cfDNA/cfRNA isolation, lab consumables, and automation. The company specializes in developing and providing cutting-edge technologies and products for liquid biopsy, genomics, and molecular diagnostics. They offer a comprehensive range of reagents, kits, lab consumables, and instruments designed to improve the efficiency and accuracy of nucleic acid extraction and analysis. The company operates in Life Sciences > Genomics, Life Sciences > Life Sciences Platforms and Tools, High Tech > Nanotechnology, Life Sciences > Oncology. Its business models include Nanotechnology > Nanoenabled Products > Life Science > Diagnostic, Oncology > In-Vitro Diagnostic Tests > Diversified, Genomics > Enabling Technologies > Kits and Reagents > NGS Reagents, Life Scie. Founded in 2017. Headquartered in United States, Sunnyvale. The company has raised funding at the Series A stage. Backed by investors including Amino Capital, ShangBay Capital, Westlake Ventures.
Apostle
Series AInnovative solutions for cfDNA/cfRNA isolation, lab consumables, and automation. The company specializes in developing and providing cutting-edge technologies and products for liquid biopsy, genomics, and molecular diagnostics. They offer a comprehensive range of reagents, kits, lab consumables, and instruments designed to improve the efficiency and accuracy of nucleic acid extraction and analysis. The company…
About
Business model
Nanotechnology > Nanoenabled Products > Life Science > Diagnostic,
Oncology > In-Vitro Diagnostic Tests > Diversified,
Genomics > Enabling Technologies > Kits and Reagents > NGS Reagents,
Life Sciences Platforms and Tools > Research Reagents and Kits > Genomics > NGS Reagents
Institutional investors
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ Explore Life Sciences investors — funds that write checks in this sector.